Good morning, it's Paul & Jack here with the SCVR for Tuesday.

Agenda - 

Paul's Section:

Beeks Financial Cloud (LON:BKS) (I hold) - I review its interim results to 12/2021. Very strong organic growth, and lots of recent contract wins, suggests the future is bright. At this stage though, it's little above breakeven, so tricky to value.

Scs (LON:SCS) (I hold) - poor H1 results, but that's against unusually strong, distorted prior year comps. Outlook comments seem confident about recouping backed up orders into revenue in H2, with an in line with expectations guidance. Balance sheet laden with cash. Looks interesting, and I'm tempted to average down.

Luceco (LON:LUCE) - 2021 results look solid. The big question, is how much the doubling of profits from 2019 to 2021 was lockdown-fuelled? A PER of 12 looks attractive, but we could have just seen peak earnings maybe? At this stage it's tricky to value, and really depends on your personal view of the macro outlook.

Knights Group (LON:KGH) - profit warning from this legal services group has collapsed the share price by an astonishing 50%. Is this an over-reaction? Possibly, but I don't know the share well enough to be sure. I don't see solvency risk, and it remains decently profitable. So there could be a trade here for a rebound, maybe? I'm more worried about the read across to the whole sector, with corporate work slowing. 


Explanatory notes -

A quick reminder that we don’t recommend any stocks. We aim to review trading updates & results of the day and offer our opinions on them as possible candidates for further research if they interest you. Our opinions will sometimes turn out to be right, and sometimes wrong, because it's anybody's guess what direction market sentiment will take & nobody can predict the future with certainty. We are analysing the company fundamentals, not trying to predict market sentiment.

We stick to companies that have issued news on the day, with market caps up to about £700m. We avoid the smallest, and most speculative companies, and also avoid a few specialist sectors (e.g. natural resources, pharma/biotech).

A key assumption is that readers DYOR (do your own research), and make your own investment decisions. Reader comments are welcomed - please be civil, rational, and include the company name/ticker, otherwise people…

Unlock the rest of this article with a 14 day trial

Already have an account?
Login here